Immunic is developing orally administered small molecule therapies targeting chronic inflammatory and autoimmune diseases, including multiple sclerosis and celiac disease. Their treatments aim to provide effective, safe, and well-tolerated options that address the debilitating symptoms associated with these conditions.
Funding
$240M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic inflammatory and autoimmune diseases, such as multiple sclerosis and celiac disease, often require long-term management with treatments that can have limited efficacy or significant side effects. Patients need oral therapies that are both effective in managing symptoms and well-tolerated to improve their quality of life.
Solution
Immunic Therapeutics is developing a pipeline of orally administered, small molecule therapies designed to selectively target key pathways involved in chronic inflammatory and autoimmune diseases. Their investigational drugs are designed to offer a balance of therapeutic efficacy, safety, and tolerability, addressing the unmet needs of patients with conditions like multiple sclerosis and celiac disease. By focusing on oral administration, Immunic aims to provide convenient treatment options that can improve patient adherence and overall outcomes. The company's programs are in clinical development, with the goal of providing differentiated therapies that elevate the standard of care for these debilitating conditions.
Target Audience
The primary target audience includes individuals suffering from chronic inflammatory and autoimmune diseases, such as multiple sclerosis and celiac disease, and the healthcare professionals who treat them.
Features
- Orally administered small molecule drugs for convenient dosing
- Selective targeting of key pathways in inflammatory and autoimmune diseases
- Vidofludimus calcium: Aims to provide a holistic solution for multiple sclerosis patients
- IMU-856: Designed to offer new treatment options for celiac disease patients
- Focus on comprehensive therapeutic efficacy and outstanding safety and tolerability